An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more alpha1 adrenergic agonists or antagonists is disclosed. The ophthalmic formulation may enable treatment of conditions adversely affecting the visual acuity of a patient, including presbyopia. A method of using the disclosed ophthalmic formulation to treat or ameliorate symptoms of presbyopia is also disclosed.

An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more al adrenergic agonists or antagonists is disclosed. The ophthalmic formulation may enable treatment of conditions adversely affecting the visual acuity of a patient, including presbyopia, A method of using the disclosed ophthalmic formulation to treat or ameliorate symptoms of presbyopia is also disclosed.

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of ...

PURPOSE: A method for isolating pilocarpine is provided to maximize the quantity of pilocarpine according to the combination of enzymes, temperature, and pH concentration. CONSTITUTION: A method for isolating pilocarpine comprises the steps of: pulverizing dried jaborandi leaves

596656 Disclosed herein is a composition comprising baclofen sorbitol and a compound selected from pilocarpine methimazole mifepristone naltrexone rapamycine flurbiprofen and ketoprofen or salts enantiomers or racemates thereof and a pharmaceutically acceptable carrier or excipient; and the use of said composition in the treatment of Charcot-Marie-Tooth disease a toxic neuropathy oamyotrophic lateral sclerosis.

PURPOSE: A composition containing a Hericium erinaceum extract for preventing or treating brain damages is provided to suppress the apoptosis of nerve cells, and to be used as a material of functional health food. CONSTITUTION: A pharmaceutical composition for preventing or treating brain damage contains a Hericium erinaceum extract as an active ingredient. The extract contains 40-250mg/kg of ethanol extract. The brain damage is epilepsy or seizure induced by pilocarpine. Health functional food ...

The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agoni...

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of ...